Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.47 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.46 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19127905 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL5084837 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL5204684 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL16884634 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL291932 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL835295 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL2825440 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL2825437 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL835150 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL21376096 | 0.91 | MAPT (0.64) | MAPTEPHX2CNR2ALDH1A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025870-A1 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Synaptogenix, Inc. (US) | 2024-01-25 | — | — | US | disclosed |
| EP-4288046-A1 | TREATMENT OF OPTIC NERVE INFLAMMATION USING PKC ACTIVATORS | Synaptogenix, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-4262777-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS USING PKC ACTIVATORS | Synaptogenix, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-4236774-A1 | METHODS OF TREATING AND PREVENTING NEURODEGENERATIVE DISEASES WITH HGF ACTIVATING COMPOUNDS | Synaptogenix, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022170226-A1 | TREATMENT OF OPTIC NERVE INFLAMMATION USING PKC ACTIVATORS | Synaptogenix, Inc. (US) | 2022-08-11 | — | — | WO | disclosed |
| WO-2022132856-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS USING PKC ACTIVATORS | Synaptogenix, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022094370-A1 | METHODS OF TREATING AND PREVENTING NEURODEGENERATIVE DISEASES WITH HGF ACTIVATING COMPOUNDS | Synaptogenix, Inc. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025870-A1 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PRKCH, PRKCA, PRKCG | MAPT 612/4885EPHX2 262/4885CNR2 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.